Ruxolitinib Phosphate and Lipid elevations
Result of checking the interaction of drug Ruxolitinib Phosphate and disease Lipid elevations for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:The use of ruxolitinib may increase total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides. It is recommended to assess lipid parameters approximately 8-12 weeks following initiation of therapy and to monitor and treat per clinical guidelines for the management of hyperlipidemia. Care should be exercised when using this agent in patients with lipids disorders.
Generic Name: ruxolitinib
Brand Name: Jakafi
Synonyms: Ruxolitinib
Ruxolitinib Phosphate - podwyższenie poziomu lipidów 
Ruxolitinib Phosphate - elevações de lipídios 
Ruxolitinib Phosphate - ketinggian lipid 
Ruxolitinib Phosphate - peningkatan lipid 
Ruxolitinib Phosphate - aumenti dei lipidi 
Ruxolitinib Phosphate - élévation des lipides 
Ruxolitinib Phosphate - Lipiderhöhungen 
Ruxolitinib Phosphate - elevaciones de lípidos 
Ruxolitinib Phosphate - повышение липидов 
Ruxolitinib Phosphate - lipid yükselmeleri 
Ruxolitinib Phosphate - ارتفاع الدهون 
Ruxolitinib Phosphate - 脂质升高